A detailed history of Advisor Group Holdings, Inc. transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 459 shares of XENE stock, worth $17,506. This represents 0.0% of its overall portfolio holdings.

Number of Shares
459
Previous 537 14.53%
Holding current value
$17,506
Previous $20,000 10.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$36.12 - $43.96 $2,817 - $3,428
-78 Reduced 14.53%
459 $18,000
Q2 2024

Aug 13, 2024

SELL
$36.25 - $43.75 $10,621 - $12,818
-293 Reduced 35.3%
537 $20,000
Q1 2024

May 10, 2024

SELL
$42.66 - $50.04 $78,281 - $91,823
-1,835 Reduced 68.86%
830 $35,000
Q4 2023

Feb 12, 2024

SELL
$28.7 - $46.46 $35,071 - $56,774
-1,222 Reduced 31.44%
2,665 $122,000
Q3 2023

Nov 13, 2023

BUY
$34.16 - $39.73 $40,855 - $47,517
1,196 Added 44.44%
3,887 $132,000
Q2 2023

Aug 10, 2023

BUY
$34.84 - $43.54 $69,993 - $87,471
2,009 Added 294.57%
2,691 $103,000
Q1 2023

May 12, 2023

BUY
$33.46 - $40.35 $200 - $242
6 Added 0.89%
682 $24,000
Q4 2022

Feb 10, 2023

BUY
$33.06 - $39.43 $2,810 - $3,351
85 Added 14.38%
676 $26,000
Q3 2022

Nov 14, 2022

BUY
$30.79 - $39.82 $10,099 - $13,060
328 Added 124.71%
591 $22,000
Q2 2022

Aug 10, 2022

BUY
$25.44 - $35.16 $4,146 - $5,731
163 Added 163.0%
263 $8,000
Q1 2022

May 04, 2022

SELL
$25.09 - $33.13 $6,899 - $9,110
-275 Reduced 73.33%
100 $3,000
Q2 2021

Aug 02, 2021

SELL
$16.81 - $20.0 $6,303 - $7,500
-375 Reduced 50.0%
375 $7,000
Q1 2020

May 18, 2020

BUY
$8.08 - $17.57 $6,060 - $13,177
750 New
750 $9,000

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.37B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.